Fennec Pharmaceuticals Inc's stock remains steady this week, reflecting recent company developments and financial performance.
Fennec Pharmaceuticals Inc (FRX.TO) has maintained a stable stock price this week, closing at C$17.00, with no significant changes in its price action. The company continues to generate interest among investors, particularly following recent positive financial results and strategic offerings.
Advertisement
Fennec Pharmaceuticals Inc
FRX.TO
FRX.TO
Fennec Pharmaceuticals Inc
WealthAwesomeMarket cap
$596.14M
52W high
$17.64
52W low
$7.59
1W change
+0.00%
Beta
1.07
Analyst Price Targets
Based on analyst covering FRX
Wall Street analysts forecast FRX stock price to rise 450.4% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$93.57
+450.4% Upside
Current Price
C$17.00
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on FRX's historical volatility
30-Day Vol
69.0%
Annualized
90-Day Vol
78.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$20.32
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$18.04 | C$14.22 – C$22.89 |
| 60 trading days | C$19.15 | C$13.68 – C$26.81 |
| 90 trading days | C$20.32 | C$13.46 – C$30.69 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Fennec Pharmaceuticals is showing strong growth potential, evidenced by its recent financial performance and market activities. Investors should closely monitor the company’s developments as it continues to navigate the healthcare sector.
Fennec Pharmaceuticals Sees 22.74% Increase Over the Last Month
The stock has experienced a notable 63.30% increase year-to-date, reflecting a positive market sentiment towards the company’s growth trajectory.
Bull case
The company has reported significant growth in net product sales, showing strong demand for its offerings. Additionally, the recent capital raised through share offerings may improve its financial stability and support future investments.
Bear case
Despite promising sales growth, Fennec Pharmaceuticals is still operating at a loss, which could raise concerns about its long-term sustainability. The stock's high beta suggests it may be more volatile than the broader market.
Price Action Overview
Fennec Pharmaceuticals Inc's stock closed at C$17.00, showing no change for the day and maintaining a steady performance over the week. The stock has appreciated 22.74% over the past month and 63.30% year-to-date, indicating a strong upward trend in investor sentiment.
Company Developments
Advertisement
Recent headlines indicate that Fennec Pharmaceuticals has been active in its financial maneuvers. The company priced an offering of common shares at $7.50 per share, aiming to raise approximately $35 million for debt repurchase and general corporate purposes. Additionally, a non-brokered private offering raised gross proceeds of $5,025,000, reflecting strong support from existing institutional shareholders.
Technical Picture
From a technical perspective, Fennec Pharmaceuticals is trading above its 50-day moving average of C$15.19, representing an 11.9% increase, and significantly above its 200-day moving average of C$11.85, which is up 43.4% from the current price. The stock has a 52-week range of C$7.59 to C$17.64, currently trading at 94% of that range. With a beta of 1.07, the stock exhibits a volatility level slightly above the market average.
Insider Activity
There are no recent reports of insider activity or significant trades disclosed by executives or board members of Fennec Pharmaceuticals.
Conclusion and Price Action Summary
In summary, Fennec Pharmaceuticals Inc's stock remains stable, closing at C$17.00 with no change from the previous day. Investors are encouraged to keep an eye on upcoming developments as the company continues to grow within the healthcare sector.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
